UMC119-06-05 / Xuanjie - LARVOL DELTA

Mesenchymal Stem Cells for Frailty Syndrome (clinicaltrials.gov) - P1/2 | N=66 | Active, not recruiting | Sponsor: Meribank Biotech Co., Ltd.

New P1/2 trial • Geriatric Disorders

Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Meribank Biotech Co., Ltd.

New P2 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Xuanjie’s new COPD drug UMC119-06-05 has been approved by the Ministry of Health and Welfare to conduct Phase II clinical trials (ctee.com) - "Xuanjie Stem Cell Biotechnology (4724) announced that the new allogeneic umbilical cord mesenchymal stem cell drug UMC119-06-05 developed has received a letter from the Ministry of Health and Welfare approving the second phase clinical trial for the treatment of chronic obstructive pulmonary disease."

Non-US regulatory • Chronic Obstructive Pulmonary Disease

Mesenchymal Stem Cells for The Treatment of Frailty Syndrome (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: Meridigen Biotech Co., Ltd. | Trial completion date: Jul 2023 ➔ Jul 2025 | Trial primary completion date: Dec 2022 ➔ Dec 2024

Trial completion date • Trial primary completion date • Geriatric Disorders

Mesenchymal Stem Cells for The Treatment of Knee Osteoarthritis (KOA). (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: Meridigen Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2023 ➔ Jun 2025 | Trial primary completion date: Sep 2022 ➔ Sep 2024

Enrollment open • Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Mesenchymal Stem Cells for The Treatment of Frailty Syndrome (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: Meridigen Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Geriatric Disorders

Mesenchymal Stem Cells for The Treatment of Frailty Syndrome (clinicaltrials.gov) - P1; N=6; Not yet recruiting; Sponsor: Meridigen Biotech Co., Ltd.

Clinical • New P1 trial • Geriatric Disorders

Mesenchymal Stem Cells for The Treatment of Knee Osteoarthritis (KOA). (clinicaltrials.gov) - P1; N=6; Not yet recruiting; Sponsor: Meridigen Biotech Co., Ltd.

Clinical • New P1 trial • Immunology • Osteoarthritis • Pain • Rheumatology • MRI